Anavex Life Sciences Corp (AVXL) Given Consensus Recommendation of “Buy” by Analysts

Shares of Anavex Life Sciences Corp (NASDAQ:AVXL) have earned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.50.

A number of equities analysts recently commented on the company. Roth Capital set a $10.00 price objective on Anavex Life Sciences and gave the stock a “buy” rating in a report on Friday. Maxim Group set a $7.00 price objective on Anavex Life Sciences and gave the stock a “buy” rating in a report on Thursday, December 13th. Finally, HC Wainwright set a $10.00 price target on Anavex Life Sciences and gave the company a “buy” rating in a report on Wednesday, October 31st.

A number of hedge funds have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in shares of Anavex Life Sciences in the 2nd quarter worth $1,749,000. Jane Street Group LLC acquired a new stake in shares of Anavex Life Sciences in the 2nd quarter worth $157,000. Finally, Hikari Power Ltd acquired a new stake in shares of Anavex Life Sciences in the 4th quarter worth $231,000. Institutional investors own 17.88% of the company’s stock.



NASDAQ:AVXL traded up $0.04 during mid-day trading on Monday, reaching $2.39. The stock had a trading volume of 477,753 shares, compared to its average volume of 144,033. Anavex Life Sciences has a fifty-two week low of $1.25 and a fifty-two week high of $4.35. The company has a market capitalization of $112.07 million, a P/E ratio of -6.13 and a beta of 2.41.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, equities analysts predict that Anavex Life Sciences will post -0.46 earnings per share for the current year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.

Featured Article: What are trading strategies for the 52-week high/low?

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply